Monday, April 29, 2024 7:06:43 PM
CARLSBAD, Calif., April 29, 2024 -- (BUSINESS WIRE) -- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) is saddened to report the passing of its long-serving Chairman of the Board of Directors, Mr. Alfred D. Kingsley, and offers its deepest condolences to Mr. Kingsley’s family for their loss. Mr. Kingsley served as Chairman of the Company’s Board of Directors since July 2009, and was a significant contributor in the evolution of the Company into a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs.
Effective as of April 27, 2024, Michael H. Mulroy, J.D., has been appointed by the Board of Directors to serve as the Chairman of the Board of Directors.
"We are incredibly saddened by Al’s passing and offer our thoughts, prayers, and support to the entire Kingsley family during this difficult time," stated Michael H. Mulroy. "Al was exceptionally committed to Lineage and its shareholders, and brought great innovation, leadership, and dedication to others to his work. Al was not only a key contributor to the company from the beginning, but also set an example for all of us through his generosity to the community. It has been a privilege to serve alongside him on the Board and we look forward to continuing to build upon his legacy."
Mr. Mulroy’s background includes experience as a biotech and biopharma corporate executive, and as a corporate attorney and investment banker. He has served as a member of the Board of Directors since 2014 and serves as Chair of the Compensation Committee and as a member of the Audit Committee and the Financial Strategy Committee. Mr. Mulroy brings extensive expertise across a number of operational and functional areas, including corporate finance and development, and clinical and strategic operations. He previously served as Chief Executive Officer and a member of the board of directors of Asterias Biotherapeutics, Inc. Prior to joining Asterias, Mr. Mulroy served as a Senior Advisor to CamberView Partners, LLC (now part of PJT Partners Inc.), which assists companies in connection with investor engagement and complex corporate governance issues. Prior to its sale in 2014, Mr. Mulroy served as Executive Vice President, Strategic Affairs and General Counsel of Questcor Pharmaceuticals, Inc. (QCOR), where he also previously served as Chief Financial Officer. Mr. Mulroy earned his J.D. degree from the University of California, Los Angeles and his B.A. degree in economics from the University of Chicago.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or "off-the-shelf," cell therapies to address unmet medical needs. Lineage’s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage’s neuroscience focused pipeline currently includes: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Eterna Therapeutics Inc. For more information, please visit https://www.lineagecell.com or follow the company on X/Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429858960/en/
Contacts
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(mailto://ir@lineagecell.com)
(442) 287-8963
LifeSci Advisors
Daniel Ferry
(mailto://daniel@lifesciadvisors.com)
(617) 430-7576
Russo Partners – Media Relations
Nic Johnson or David Schull
(mailto://Nic.johnson@russopartnersllc.com)
(mailto://David.schull@russopartnersllc.com)
(212) 845-4242
Recent LCTX News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/15/2024 04:15:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:39:15 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/14/2024 08:36:06 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:15:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:10:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:05:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:05:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:05:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/07/2024 10:17:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:10:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 10:27:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 02:30:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 02:27:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 11:58:18 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/08/2024 11:57:07 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/06/2024 02:25:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:20:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/06/2024 02:00:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 12:08:49 AM
- Take Part in the Next Generation of Spinal Cord Injury Treatments with These Companies • AllPennyStocks.com • 11/16/2023 09:21:00 PM
- Take Part in the Next Generation of Spinal Cord Injury Treatments with These Companies • AllPennyStocks.com • 11/16/2023 09:21:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 11/13/2023 09:19:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:10:32 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM